Meningioma (University of Toronto, Nature Genetics 2021)

Overview

Multi-platform integrative meningioma cohort from the University Health Network Brain Tumor BioBank (Toronto), enriched for WHO grade 2 and 3 tumors. Used to develop a clinically applicable integrative molecular classification (MG1–MG4). An 80-sample independent validation cohort was assessed with mRNA signatures. Data deposited in cBioPortal as mng_utoronto_2021. PMID:34433969

Composition

  • 121 fresh-frozen meningiomas from the University Health Network Brain Tumor BioBank, plus 5 healthy meninges controls; enriched for WHO grade 2 and 3 tumors. PMID:34433969
  • 80 independent meningiomas in validation cohort assessed using mRNA signatures. PMID:34433969
  • Cancer type: MNG (meningioma). PMID:34433969

Assays / panels (linked)

Papers using this cohort

  • PMID:34433969 — A Clinically Applicable Integrative Molecular Classification of Meningiomas.

Notable findings derived from this cohort

  • COCA integration of CNA, DNA methylation, and mRNA clusters identified four stable molecular groups (MG1–MG4), independently associated with recurrence-free survival after adjusting for WHO grade (log-rank P=5×10^-15). PMID:34433969
  • MG classification was superior to WHO grade, methylation-based classification, and individual-datatype clustering for predicting time to recurrence. PMID:34433969
  • NF2 mutated in 88% of MG1 vs. 9% of MG2 tumors (P=5.9×10^-8); non-NF2 drivers (TRAF7 25%, AKT1 13%, KLF4 13%, POLR2A 6%) exclusive to MG2. PMID:34433969
  • Novel recurrent driver mutations in KDM6A, CHD2, and PTEN enriched in MG3/MG4 (P=0.002). PMID:34433969

Sources

This page was processed by entity-page-writer on 2026-04-11.